VistaGen Therapeutics Current Ratio 2008-2021 | VTGN

VistaGen Therapeutics current ratio from 2008 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
VistaGen Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.10B $0.01B 15.93
2021-03-31 $0.10B $0.00B 24.86
2020-12-31 $0.11B $0.00B 35.22
2020-09-30 $0.02B $0.00B 4.84
2020-06-30 $0.00B $0.00B 0.82
2020-03-31 $0.00B $0.00B 0.57
2019-12-31 $0.00B $0.00B 0.47
2019-09-30 $0.01B $0.00B 1.14
2019-06-30 $0.01B $0.00B 2.65
2019-03-31 $0.01B $0.00B 4.87
2018-12-31 $0.01B $0.00B 3.63
2018-09-30 $0.01B $0.00B 6.48
2018-06-30 $0.01B $0.00B 4.19
2018-03-31 $0.01B $0.00B 7.56
2017-12-31 $0.01B $0.00B 10.53
2017-09-30 $0.00B $0.00B 1.24
2017-06-30 $0.00B $0.00B 2.12
2017-03-31 $0.00B $0.00B 2.47
2016-12-31 $0.01B $0.00B 3.08
2016-09-30 $0.01B $0.00B 3.84
2016-06-30 $0.01B $0.00B 5.39
2016-03-31 $0.00B $0.00B 0.48
2015-12-31 $0.00B $0.00B 0.90
2015-09-30 $0.00B $0.00B 0.77
2015-06-30 $0.00B $0.00B 0.49
2015-03-31 $0.00B $0.02B 0.01
2014-12-31 $0.00B $0.01B 0.01
2014-09-30 $0.00B $0.01B 0.03
2014-06-30 $0.00B $0.01B 0.09
2014-03-31 $0.00B $0.01B 0.01
2013-12-31 $0.00B $0.01B 0.01
2013-09-30 $0.00B $0.00B 0.05
2013-06-30 $0.00B $0.00B 0.08
2013-03-31 $0.00B $0.00B 0.28
2012-12-31 $0.00B $0.00B 0.04
2012-09-30 $0.00B $0.00B 0.11
2012-06-30 $0.00B $0.00B 0.12
2012-03-31 $0.00B $0.00B 0.08
2011-12-31 $0.00B $0.00B 0.13
2011-09-30 $0.00B $0.01B 0.07
2011-06-30 $0.00B $0.01B 0.28
2011-03-31 $0.00B $0.01B 0.02
2010-12-31 $0.00B 0.00
2010-09-30 $0.00B $0.00B 0.68
2010-06-30 $0.00B $0.00B 1.27
2010-03-31 $0.00B $0.00B 0.83
2009-12-31 $0.00B 0.00
2009-09-30 $0.00B $0.00B 1.11
2009-06-30 $0.00B $0.00B 1.00
2009-03-31 $0.00B $0.00B 2.17
2008-12-31 $0.00B $0.00B 8.07
2008-09-30 $0.00B $0.00B 0.05
2008-06-30 $0.00B $0.00B 0.05
2008-03-31 $0.00B 0.00
2007-12-31 $0.00B $0.00B 0.50
2007-09-30 $0.00B 0.00
2007-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.546B $0.001B
VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29